Evidence map›Paper›PMID 36038676›Full record

ArticleJournal of cancer research and clinical oncology2023

Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.

Jiantao Fu, Feng Chen, Yuanji Lin, Jin Gao, Anna Chen, Jin Yang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jiantao Fu *Department of Translational Medicine Center, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, China.
Feng Chen *Department of Blood Bank, Blood Center of Zhejiang Province, Hangzhou, 310052, Zhejiang, China.
Yuanji LinDepartment of Research, Hangzhou MC Life Sciences Co., Ltd, Hangzhou, 311500, Zhejiang, China.
Jin GaoDepartment of Translational Medicine Center, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, China.
Anna ChenDepartment of Translational Medicine Center, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, China.
Jin YangDepartment of Translational Medicine Center, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, China. 20171129@hznu.edu.cn.
Affiliated Hospital of Hangzhou Normal University · CNBlood Center of Zhejiang Province · CNHangzhou Normal University · CN

Funding

Medical Science and Technology Project of Zhejiang Province 2018PY039National Natural Science Foundation of China 81772520Natural Science Foundation of Zhejiang Province LGF19H030004
6 · The paper itself

Abstract

backgroundmRNA vaccines are emerging as new targets for cancer immunotherapy. However, the potential tumor antigens for mRNA vaccine design in hepatocellular carcinoma (HCC) remain to be elucidated.

methodsGenetic and RNA-Seq data were obtained from TCGA and ICGC. Tumor-specific antigens (TSAs) were identified by differential expression, mutation status, HLA binding, antigen-presenting cell (APC) correlation, immune checkpoint (ICP) relevance and prognosis. Consensus clustering was used for patient classification. The molecular and immune status of TSAs and clustered patients, including prognostic ability, tumor microenvironment, tumor-related signature and tumor immune dysfunction and exclusion (TIDE), were further characterized.

resultsFive dysregulated and mutated TSAs were identified in HCC (TSA5): FXYD6, JAM2, GALNT16, C7, and CCDC146. Seven immune gene modules and five immune subtypes (IS1-IS5) of HCC were identified. The immune subtypes and TSA5-related modules showed distinct molecular, cellular and clinical characteristics. According to our study, IS1 patients may be suitable for vaccination.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAntigens, NeoplasmHumansmRNA VaccinesRNA, MessengerTumor MicroenvironmentAntigens, NeoplasmmRNA VaccinesRNA, MessengerHepatocellular carcinomaImmune subtypesImmunologymRNA vaccineTumor antigens

Identifiers

PMID36038676
PMCPMC9423891
OpenAlexW4293718669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.